MedLumics secured €34.4 million in financing to advance the development of its innovative AblaView catheter for treating atrial fibrillation, marking a significant investment in Spain's medtech sector.

Information on the Target

MedLumics is a pioneering cardiac device company, founded in 2009, that specializes in optically guided minimally invasive instruments. With its proprietary integrated optics platform technology, the company creates innovative medical devices that combine optical and electrical components into a miniature chip. This novel approach enables the development of complex multiview optical probes and portable OCT systems, aimed at enhancing diagnostic and therapeutic procedures through non-invasive tissue evaluation.

Recently, MedLumics announced a successful financing round of 34.4 million Euros, the largest investment in the medtech sector in Spain and one of the most significant in Europe this year. The funds will primarily be allocated towards advancing the product and clinical development of the AblaView catheter, specifically intended for treating atrial fibrillation (AF) and other arrhythmias.

Industry Overview in Spain

The medical technology industry in Spain has seen substantial growth in recent years, largely driven by the increasing demand for innovative healthcare solutions. With a focus on enhancing patient outcomes, numerous companies are investing in cutting-edge technologies to addr